Blog

Orange neon glowing sine wave and a blue trigonometric curve reflected by mirrors in black background. Illustration of the concept of technology, science and mathematics

Electric medicine, a sub-sector of healthtech, is a rapidly growing field that uses electrical energy to treat diseases and conditions. This trend is attracting significant investment from venture capital firms and is driving strategic acquisitions within the medical technology (medtech) industry.&nbsp;⚡️ What is Electric Medicine? Electric medicine, also known as bioelectric medicine or electroceuticals, involves using electrical impulses to stimulate or block nerve signals to treat a variety of conditions. Instead of traditional pharmaceuticals, these treatments use devices that interface with the body's nervous system.Key applications include:Pain management: Devices like Transcutaneous Electrical Nerve Stimulation (TENS) units for chronic pain relief.Neurological disorders: Deep brain stimulators for conditions like Parkinson's disease and epilepsy.Cardiology: Implantable cardioverter-defibrillators (ICDs) and pacemakers for heart rhythm disorders.Mental health: Electroconvulsive therapy (ECT) and vagus nerve stimulation for severe depression.💰 Increasing Venture Capital Investment While overall venture capital funding in healthtech has experienced some fluctuations, investment in specific, high-growth areas like electric medicine and AI-driven solutions is surging. The market for bioelectric medicine was valued at over $21 billion in 2022 and is projected to reach over $35 billion by 2030. This growth is driven by the rising prevalence of chronic conditions and an aging population.Venture capitalists are drawn to electric medicine for several reasons:Proven Technology: Many of these devices, such as pacemakers, have long-standing clinical validation. Non-invasive Potential: The development of non-invasive electroceuticals is a particularly attractive area for investment.Regulatory Pathway: Unlike drug development, which can be a 10-15 year process, medical device development often has a more defined and potentially faster regulatory path.Value-based Care: These technologies align with the shift toward value-based care by offering solutions that can improve patient outcomes and reduce long-term healthcare costs. 🤝 Strategic Acquisitions The electric medicine trend is also fueling strategic acquisitions as larger medical device companies seek to expand their portfolios and stay competitive. Instead of focusing on incremental improvements to existing products, companies are acquiring smaller, innovative startups to gain access to new technologies and expand into high-growth markets.Recent strategic acquisitions in the medtech space include:Johnson &amp; Johnson's acquisition of Abiomed for its heart pump technology and Shockwave Medical for its cardiovascular devices. Stryker's acquisition of Inari Medical for its vascular clot removal solutions.Boston Scientific's acquisition of Relievant Medsystems for its pain management solutions and Axonics for its sacral neuromodulation systems.These acquisitions are driven by a need to integrate new technologies, strengthen product portfolios, and position companies as leaders in emerging fields like electrophysiology, neuromodulation, and vascular health. This M&amp;A activity is expected to continue as the market for electric medicine and related healthtech solutions expands.To discuss how Nelson Advisors can help your HealthTech or MedTech company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a>

Electric Medicine attracting investment and driving strategic acquisitions

Ambient voice technology, often referred to as ambient AI or AI scribes, is a rapidly evolving field with significant predicted growth for 2026. The technology is moving from being a simple dictation tool to an intelligent "co-pilot" that passively listens to conversations and automatically generates notes, reports, and other documentation. The predictions for 2026 are largely driven by a combination of technological advancements, market demand, and strategic initiatives, particularly within the healthcare sector.Key Predictions for 20261. Mainstream Adoption, Especially in Healthcare2026 is poised to be a pivotal year for the widespread adoption of ambient voice technology, particularly in healthcare settings. The administrative burden on clinicians is a major challenge, and AVT is seen as a key solution. Trials and pilot programs in organizations like the UK's NHS and various health systems in the US have shown significant benefits, including:Reduced Administrative Time: Clinicians can save a substantial amount of time—estimated at 10 to 15 minutes per patient encounter—by no longer needing to manually type notes. Improved Clinician Satisfaction: By alleviating burnout from paperwork, AVT allows doctors and nurses to focus more on patient care and less on administrative tasks. Enhanced Patient Experience: With clinicians making more eye contact and being more present, patient satisfaction is expected to increase. 2. Shift from Dictation to "True Ambient" FunctionalityCurrent AVT systems often require a voice prompt or a button press to start and stop recording. In 2026, the technology is expected to become more truly "ambient," operating passively in the background with advanced microphone arrays and AI to capture conversations without explicit activation. This will enable a more seamless and natural workflow.3. Integration and InteroperabilityThe push for seamless integration with existing systems, particularly Electronic Health Records (EHRs), will be a major trend. Vendors are focusing on creating solutions that can easily and securely transfer data, eliminating the need for clinicians to manually move information. This is critical for unlocking the full value of the technology.4. Advanced AI and Multilingual CapabilitiesThe underlying AI models, particularly Large Language Models (LLMs), will become more sophisticated. This will lead to:Higher Accuracy: Improved speech recognition will be able to handle diverse accents, dialects, and complex medical terminology with near-perfect accuracy. Multilingual Support: As healthcare systems serve diverse populations, AVT will need to offer robust multilingual capabilities, allowing for real-time translation and documentation in various languages. 5. Evolution of the Regulatory LandscapeAs AVT becomes more prevalent, the regulatory environment will continue to mature. In 2026, there will be an increased focus on:Clinical Safety: New regulations and guidelines will be established to ensure the technology does not introduce errors or "hallucinations" that could compromise patient care. Data Privacy and Security: The use of patient data for AI training and documentation will be subject to strict data protection laws, such as HIPAA in the US and GDPR in Europe. Growth Drivers and ChallengesGrowth Drivers:Demand for Productivity: Both the public and private sectors are under immense pressure to improve productivity and efficiency, making AVT a highly attractive investment. Government Initiatives: In places like the UK, government-led digital transformation plans are explicitly calling for the use of AI scribes, backed by significant funding. Technological Maturity: The rapid evolution of AI, particularly in natural language processing (NLP), has made ambient voice technology both accurate and scalable. Challenges:Cost and Implementation Hurdles: While the long-term benefits are clear, the initial cost of adoption and the complexity of integrating new technology into legacy systems can be a barrier for some organizations. Ethical Concerns: Issues like potential algorithmic bias and the need for continuous human oversight to prevent AI errors will require careful management. To discuss how Nelson Advisors can help your Healthcare AI company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a>

Ambient Voice Technology predictions 2026

AI agent and generative artificial intelligence. Robotic processes automation and data analysis.

The premise that small language models (SLMs) are the future of agentic AI in healthcare is a powerful one, and it's gaining significant traction among researchers and industry leaders. While large language models (LLMs) like GPT-4 have captured public imagination, their size and resource requirements present significant barriers to real-world, scalable, and safe deployment in clinical settings. SLMs, on the other hand, are emerging as a more practical and effective solution for building specialized AI agents.Why Small Language Models are a Good Fit for Healthcare AgentsPrivacy and Security (Local Deployment): Patient data is highly sensitive and protected by strict regulations like HIPAA in the US and GDPR in Europe. LLMs typically require massive cloud-based servers, meaning data must be transmitted to a third party. SLMs, with their smaller footprint, can be deployed on-premise, on local hospital servers, or even on "edge" devices like a doctor's tablet or a patient's wearable. This keeps protected health information (PHI) within a secure, closed network, significantly reducing privacy risks and simplifying compliance.Cost-Effectiveness and Efficiency: The computational resources required to run and scale LLMs are immense, leading to high costs and latency. SLMs are far more efficient. They are cheaper to train, require less computational power for inference (generating responses), and have lower energy consumption. This makes them economically viable for a wide range of use cases within a hospital or a health system, where an LLM's cost would be prohibitive.Specialisation and Accuracy: General-purpose LLMs are "Jacks of all trades," trained on vast amounts of internet data. This can be a liability in healthcare, where a model might "hallucinate" or provide inaccurate information because it's not a medical specialist. SLMs, in contrast, can be fine-tuned on highly specific, high-quality medical datasets, such as clinical notes, radiology reports, or biomedical research papers. This domain-specific training makes them highly accurate for a narrow range of tasks, which is exactly what a specialized AI agent needs.Explainability and Trust: In healthcare, it's not enough for an AI to be right; clinicians need to understand why it made a certain recommendation. This is crucial for building trust and for legal accountability. Because of their simpler architecture and more focused training data, SLMs are often more transparent and easier to audit than massive "black box" LLMs. This helps to ensure that the AI's reasoning can be understood and validated by a human.The Agentic AI Revolution in HealthcareAn "agentic AI" is an autonomous system that can perceive its environment, plan, and take actions to achieve a goal. While LLMs can provide the "brain" for these agents, SLMs are the ideal fit for the practical, day-to-day tasks of a healthcare agent.Here's how an SLM-powered agent could work in practice:Administrative Agent: An SLM agent could autonomously manage a patient's journey. It could detect a doctor's request in a clinical note to "schedule a follow-up with cardiology in 2 weeks," then independently access the scheduling system, find an available slot, send a patient notification, and update the EHR, all without human intervention.Clinical Support Agent: An agent trained on a hospital's specific protocols and a patient's medical history could continuously monitor real-time data from a patient's wearable device. If it detects a sudden change in heart rate, it could autonomously flag the issue to a nurse, summarize the patient's recent history, and recommend a specific protocol for intervention.Medical Literature Agent: An SLM agent could be given a complex patient case and a list of symptoms. It could then autonomously sift through thousands of recent medical journals and clinical trial reports to find and summarize the most relevant findings, saving a clinician hours of research time.Challenges and OutlookDespite the promise, deploying SLMs as agents in healthcare faces challenges. The upfront costs of setting up the necessary infrastructure, the need for high-quality training data, and the importance of continuous auditing and monitoring are significant hurdles.However, companies like NVIDIA are actively developing frameworks and tools to make this process easier. The move towards specialized, on-premise AI, with a focus on efficiency and safety, suggests that the future of agentic AI in healthcare will likely be built on a foundation of small, specialized language models rather than a few massive, general-purpose ones.To discuss how Nelson Advisors can help your Health AI company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>

Why Small Language Models are a Good Fit for Healthcare Agents

Happy new year. A businessman draws a line rising up, from 2025 to  2026, representing aimed growth, achievement, and success,to start and welcome the new coming year.

Based on the current trends and priorities shaping the European healthtech landscape, here's an overview of the key priorities for founders, investors, buyers, and sellers in 2026.For Founders Focus on Clinical and Financial Outcomes: The market is maturing, and the focus is shifting from "cool tech" to solutions that can demonstrate tangible value. Founders need to show not just that their product works, but that it leads to measurable improvements in patient outcomes, cost reduction, or operational efficiency for healthcare systems.Emphasise Capital Efficiency: With a tighter capital market, investors are scrutinizing business models more closely. Startups that can prove they have a clear path to profitability, manage a lean burn rate, and have a sustainable business model will be more attractive.Build Scalable Partnerships: Strategic partnerships are crucial for growth in the European healthtech ecosystem.Founders should prioritise integrations with major electronic health records (EHRs), payers, or health systems. This includes aligning with the priorities of organizations like the NHS in the UK or Integrated Care Systems (ICSs).Navigate the Regulatory Environment: Europe's regulatory landscape is complex, with new regulations like the AI Act and the European Health Data Space (EHDS) coming into effect. Founders must demonstrate a deep understanding of these rules, especially concerning data privacy (GDPR) and medical device certification (MDR).Specialise in High-Demand Areas: Certain sectors are attracting significant interest. These include:Generative AI: Moving beyond pilots to proven, revenue-generating applications.Remote Patient Monitoring (RPM): Enabling care outside of traditional hospital settings, especially for chronic disease management.Value-Based Care Enablers: Tools that help providers succeed under risk-based payment models.Mental Health Solutions: Moving beyond basic teletherapy to AI-driven care coordination and digital therapeutics.FemTech: This historically underfunded sector is gaining momentum, with a focus on solutions that can be reimbursed by payers. For Investors Prioritise Clinical Validation and Measurable ROI: Investors are no longer funding a "vision" alone. They are looking for companies that have proven clinical validation and can show a clear return on investment (ROI) for their customers. Seek Out Data-Driven and AI-Powered Solutions: AI is a major focus, but investors are looking for more than just the buzzword. They want to see proprietary algorithms, strong intellectual property (IP), and solutions that ethically leverage health data for diagnostics, analytics, and personalised medicine.Focus on Scalability and Market Fit: Investors are interested in companies with scalable business models, often Software-as-a-Service (SaaS), that can be rapidly deployed without disproportionate cost increases. They are also looking for a clear strategic fit within the European market, which means alignment with public health initiatives and local regulatory frameworks.Look for Strong and Credible Teams: A capable leadership team with both technical innovation and clinical insight is a key differentiator. A strong advisory board with strategic access to key industry players is also highly valued.Be Prepared for a Competitive Landscape: While the overall venture market may have cooled, there is significant competition for "Tier A" assets. Investors are using flexible deal structures and capitalizing on favorable financing conditions to secure promising opportunities.For Buyers and Sellers Prioritise Value-Based Care Alignment: Buyers, particularly health plans and providers, are increasingly focused on solutions that enable the shift to value-based care. Sellers who can demonstrate how their product helps reduce costs, improve outcomes, and manage populations will be in a strong position.Demand Interoperability and Data Management: Buyers are seeking solutions that can seamlessly integrate with their existing IT infrastructure, including EHRs. Data is seen as the backbone of modern healthcare, so sellers with advanced data analytics, secure data management, and interoperability will be highly valued.Focus on Strategic Innovation: Buyers are looking to acquire or partner with companies that offer disruptive potential. This includes cutting-edge AI, telehealth platforms, and digital therapeutics that can redefine care delivery.Demonstrate Regulatory Compliance: Regulatory readiness is a critical driver for buyers and sellers. For a seller, having a proven track record of navigating complex regulations (e.g., CE certification, GDPR compliance) significantly increases their value. For a buyer, acquiring a company with strong compliance reduces risk and ensures a smoother integration process.Look for Proven Financials and Scalability: Sellers with consistent revenue growth, a clear path to profitability, and a scalable business model will attract the most interest. Buyers are looking for targets that can be integrated to create synergies, expand their market reach, and ultimately drive revenue growth.To discuss how Nelson Advisors can help your HealthTech, MedTech or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>

HealthTech Europe 2026: what are the key priorities for founders, investors, buyers and sellers?

Initial public offering hologram, night panoramic city view of Bangkok. The financial center for multinational corporations in Asia. The concept of boosting the growth by IPO process. Double exposure.

Hinge Health, Omada Health, and HeartFlow have all recently gone public in mid-2025. Their successful IPOs have been seen as a positive sign for the digital health sector, but the market for public listings is still considered cautious. The next wave of digital health IPOs is expected to be defined by companies that share similar characteristics to these recent successes: a clear path to profitability, a strong business model, and clinically validated outcomes.&nbsp;While it is impossible to predict with certainty which companies will go public next, some of the most likely candidates for late 2025 and 2026 are those that have already achieved significant scale and have a strong market position. These companies are often leveraging AI to improve efficiency and care delivery, and they are focused on large, recurring revenue categories within healthcare.Some companies that analysts and market observers are watching as potential IPO candidates for the next wave include:Sword Health: A direct competitor to Hinge Health in the digital musculoskeletal (MSK) space. Aledade: A company that helps independent primary care practices transition to value-based care.Quantum Health: A care-coordination and navigation platform that helps employees and their families navigate the healthcare system.Transcarent: A consumer-directed health and care platform that aims to simplify the healthcare experience.Thyme Care: A value-based oncology care platform that partners with health plans and providers to improve outcomes for cancer patients.The successful debuts of Hinge Health, Omada Health, and HeartFlow have demonstrated that public markets are willing to invest in digital health, but they are looking for maturity and financial discipline. Companies that are "IPO-ready" will have to demonstrate a path to profitability, strong revenue growth, and a clear value proposition for their customers and investors. The focus has shifted from "growth at all costs" to sustainable, scalable business models.

When and who are the next wave of Digital Health IPO's coming in 2025 or 2026? After Hinge Health, Omada Health, Heartflow?

Financial graph overlay on city skyline with upward trend and growth arrows.

General HealthTech Valuations in Europe (2025)The European healthtech M&amp;A market has been active in 2025, with a notable increase in deal volume and value. While the overall trend is positive, valuations are becoming more selective, with a strong emphasis on profitability, proven business models, and strategic value.Average Revenue Multiples (EV/Revenue): The average revenue multiple for general healthtech companies in Europe is typically in the range of 4x-6x. Some reports from Q1 2025 cited a more precise average of 4.8x.Average EBITDA Multiples (EV/EBITDA): For healthtech companies with positive earnings, the enterprise value to EBITDA multiple is generally observed between 10x-14x, a slight increase from the 2024 range.Digital Therapeutics (DTx) Specific Trends and Multiples Digital therapeutics, as a specialized and high-growth sub-sector of healthtech, can command premium valuations, especially for companies with certain characteristics.Premium for AI and Innovation: Companies with proprietary AI solutions, robust data platforms, or those adjacent to the biotech sector are attracting heightened interest. These firms can see multiples rise to 6x-8x revenueor even higher, well above the sector average. This premium reflects a buyer's willingness to invest in technology that delivers measurable cost savings and improved patient outcomes.Focus on Clinical Validation and Reimbursement: The market is maturing, and investors are demanding more than just a good idea. They are looking for companies with:Clinically proven datasets. Clear regulatory and reimbursement pathways.Defensible business models, often linked to value-based care.Shift to Value-Based Care: Digital therapeutics that enable a shift from fee-for-service to value-based care are particularly attractive. Solutions for chronic disease management and population health analytics are gaining traction with payers and providers, and these companies can see multiples climb to 5.5x-7x revenue.M&amp;A Activity and "Selective Scale": The first half of 2025 has seen a trend of "selective scale" in the digital health sector. While overall funding has declined, the average deal size for late-stage financings has increased. This signals a global reallocation of capital towards more substantial, proven investments rather than a broad, speculative approach. M&amp;A activity is largely driven by consolidation, with larger entities acquiring smaller, specialized firms to broaden their portfolios.Market Context and DriversSeveral factors are shaping the valuation landscape in 2025:AI Integration: Artificial intelligence is a primary driver of valuation, as firms with proprietary AI algorithms for diagnostics, drug discovery, or patient care are seeing heightened interest.Regulatory Clarity: In Europe, regulatory bodies like the EMA are refining frameworks for digital health tools, which boosts investor confidence and can lead to a lift in multiples for compliant firms.Chronic Disease Management: The rising prevalence of chronic conditions like diabetes and obesity is creating a strong demand for effective digital health interventions, making this a key growth area.Private Equity Interest: Private equity firms are increasingly active in the European healthtech space, competing with strategic buyers for attractive assets. This is driving up competition and, in some cases, valuations for high-quality companies.To discuss how Nelson Advisors can help your HealthTech, MedTech or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>

Nelson Advisors

Blog

Electric Medicine attracting investment and driving strat...

Ambient Voice Technology predictions 2026

Why Small Language Models are a Good Fit for Healthcare A...

HealthTech Europe 2026: what are the key priorities for f...

When and who are the next wave of Digital Health IPO's co...

HealthTech Valuations in Europe 2025 - Digital Therapeuti...